S1099
Clinical – Upper GI
ESTRO 2026
forms, although both completed therapy without incidents.Neoadjuvant cases are scheduled for surgery, and pathological response data will be collected. Descriptive analysis has not yet shown statistically significant trends due to the small cohort size; formal correlations between PRO changes and dosimetric parameters will be performed as follow-up
Radiation Oncology, Hospital Fundación Jiménez Díaz, Madrid, Spain
Purpose/Objective: To assess feasibility and early patient-reported outcomes (PROs) in a newly initiated single-centre prospective cohort of esophageal cancer patients treated with radical or neoadjuvant chemoradiotherapy (CRT), and to explore correlations between PRO domains, treatment intent, and dosimetric parameters. Material/Methods: Since August 2025, patients with histologically confirmed esophageal carcinoma have been prospectively enrolled for curative-intent CRT at a single academic institution. Radical CRT delivered 50 Gy to gross disease plus 45 Gy to elective regions in 25 fractions, while neoadjuvant CRT followed the CROSS regimen (41.4 Gy in 23 fractions). PROs (EORTC QLQ- C30, QLQ-OES18) were collected at baseline and after treatment; follow-ups are planned at 3, 6 and 12 months. Dosimetric variables included PTV Dmax/Dmean, lung Dmean and V20, heart Dmean and V30, and spinal-cord Dmax. Results: Seven patients were included between August and October 2025 (median age 63 years, range 55–67). Tumours were located in the upper (n = 2), mid (n = 2), mid-distal (n = 2) and distal (n = 1) esophagus; histology comprised adenocarcinoma (n = 2) and squamous-cell carcinoma (n = 5). Four patients received radical CRT and three neoadjuvant CRT. All completed treatment as planned, except two still under therapy.
data mature. Conclusion:
This single-centre prospective cohort demonstrates the feasibility of systematic PRO collection (EORTC QLQ-C30/OES18) in patients receiving radical or neoadjuvant CRT for esophageal cancer. Early results confirm good tolerance and expected short-term QoL decline mainly related to swallowing. Ongoing follow- up will assess recovery and potential links between dosimetric exposure, treatment intent, and pathological outcomes. References: Fontes F., Fernandes D., et al. “Patient-Reported Outcomes after Surgical, Endoscopic, or Radiological Techniques for Nutritional Support in Esophageal Cancer Patients: a Systematic Review.” Current Oncology. 2024;31(10):6171-6190. DOI:10.3390/curroncol31100460.Shi S., Zhou H., Li L. et al. “Comparison of neoadjuvant chemoradiotherapy versus chemoradiotherapy plus immunotherapy for esophageal squamous cell carcinoma in a real-world multicenter cohort: a propensity score matching study.” Scientific Reports. 2024;14:24738. DOI:10.1038/s41598-024-24738. Keywords: patient-reported outcomes, dosimetry Digital Poster 3357 Stereotactic Body Radiotherapy for Isolated Local Recurrence from Pancreatic Cancer Mauro Loi 1 , Michele Aquilano 1 , Marianna Valzano 1 , Laura Masi 2 , Raffaela Doro 2 , Pierluigi Bonomo 1 , Gabriele Simontacchi 1 , Alessandra Galardi 1 , Pietro Garlatti 1 , Vanessa Di Cataldo 1 , Viola Salvestrini 1 , Olga Ruggieri 3 , Andrea Rampini 1 , Beatrice Bettazzi 1 , Matteo Mariotti 1 , Giulio Frosini 1 , Livia Marrazzo 4 , Cecilia Petruccioli 1 , Luisa Caprara 1 , Marco Banini 1 , Giulio Francolini 1 , Lorenzo Livi 1 1 Radiation Oncology Department-Careggi Hospital, University of Florence, Florence, Italy. 2 Medical Physics, IFCA, Florence, Italy. 3 Radiation Oncology, IFCA, Florence, Italy. 4 Medical Physics, University of Florence, Florence, Italy
Representative dosimetry showed PTV Dmax ≈ 54 Gy, lung Dmean 9–15 Gy, heart Dmean 8–27 Gy (V30 0– 45%), and spinal-cord Dmax 29–38 Gy. Two patients presented complete oral intolerance from baseline and required nasogastric feeding tubes. One, under neoadjuvant CRT, was replanned at fraction 15/23 due to marked tumour shrinkage and regained partial oral tolerance. The other, treated with radical CRT, had a pre-existing tracheostomy from a previous laryngeal carcinoma and was replanned at fraction 3/25 for local inflammation. These two patients have not completed baseline questionnaires. Two additional patients have finished CRT but not yet returned post-treatment
Purpose/Objective: Background: Despite metastatic failure is the
dominant pattern of relapse after primary treatment ofpancreatic cancer (PC), isolated local recurrence (ILR) may occur in a significant proportion of
Made with FlippingBook - Share PDF online